Radiofrequency ablation for lung tumors: outcomes, effects on survival, and prognostic factors

PURPOSE We aimed to evaluate the survival benefit achieved with radiofrequency (RF) ablation of prima-ry and metastatic lung tumors and determine significant prognostic factors for recurrence-free survival.METHODSForty-nine patients with lung cancer (10 primary and 39 metastatic) underwent computed to-mography-guided percutaneous RF ablation between June 2005 and October 2013. A total of 112 tumors (101 metastatic and 11 primary non-small cell lung cancer) were treated with RF ablation. Tumor diameter ranged from 0.6 to 4 cm (median 1.5 cm). Effectiveness of treatment, complications, and survival were analyzed.RESULTSPrimary success rate was 79.5% and local tumor progression occurred in 23 tumors. Among tumors showing progression, 10 were re-treated with RF ablation and secondary success rate was 87.5%. One-, two-, and three-year overall survival rates of 10 patients with primary lung cancer were 100%, 86%, and 43%, respectively. One-, two-, three-, four-, and five-year overall survival rates for 39 patients with metastatic lung tumors were 90%, 73%, 59%, 55%, and 38%, respectively. One-, two-, three-, and four-year overall survival rates for 16 patients with colorectal pulmonary metastases were 94%, 80%, 68%, and 23%, respectively. Complications occurred in 30 sessions (24.6%). Pneumothorax occurred in 19 sessions with seven requiring image-guided percutaneous chest tube drainage. Tumor status (solitary or multiple) and presence of extrapul-monary metastasis at initial RF ablation were significant prognostic factors in terms of recur-rence-free survival.CONCLUSIONRF ablation is a safe and effective treatment with a survival benefit for selected patients with primary and secondary lung tumors.

___

Youlden DR, Cramb SM, Baade PD. The Inter- national Epidemiology of Lung Cancer: geo- graphical distribution and secular trends. J Thorac Oncol 2008; 3:819-831. [CrossRef]

Scott WJ, Howington J, Feigenberg S, Movsas B, Pisters K. Treatment of non-small cell lung can- cer stage I and stage II. ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007; 132:S234-242.

Dienemann H. Principles of surgical treatment in localized non-small cell lung cancer. Lung Cancer 2001; 1:S3-8. [CrossRef]

Pearson FG. Current status of surgical resection for lung cancer. Chest 1994; 106:S337-339. [CrossRef]

Ketchedjian A, Daly B, Luketich J, Fernando HC. Minimally invasive techniques for managing pulmonary metastases: video-assisted thoracic surgery and radiofrequency ablation. Thorac Surg Clin 2006; 16:157-165. [CrossRef]

Mitry E, Guiu B, Cosconea S, Jooste V, Faivre J, Bouvier AM. Epidemiology, management and prognosis of colorectal cancer with lung me- tastases: a 30-year population-based study. Gut 2010; 59:1383-1388. [CrossRef]

Pfannschmidt J, Dienemann H, Hoffmann H. Surgical resection of pulmonary metastases from colorectal cancer: a systematic review of published series. Ann Thorac Surg 2007; 84:324-338. [CrossRef]

Dupuy DE, Zagoria RJ, Akerley W, Mayo-Smith WW, Kavanagh PV, Safran H. Percutaneous ra- diofrequency ablation of malignancies in the lung. AJR Am J Roentgenol 2000; 174:57-59. [CrossRef]

Dupuy DE, Goldberg SN. Image-guided ra- diofrequency tumor ablation: challenges and opportunities-part II. J Vasc Interv Radiol 2001; 12:1135-1148. [CrossRef]

Pereira PL, Masala S. Standards of practice: guidelines for thermal ablation of primary and secondary lung tumors. Cardiovasc Intervent Radiol 2012; 35:247-254. [CrossRef]

Hiraki T, Mimura H, Gobara H, et al. Repeat ra- diofrequency ablation for local progression of lung tumors: does it have a role in local tumor control? J Vasc Interv Radiol 2008; 19:706-711. [CrossRef]

Tatli S, Tapan U, Morrison PR, Silverman SG. Ra- diofrequency ablation: technique and clinical applications. Diagn Interv Radiol 2012; 18:508- 516.

Baumann MH, Strange C, Heffner JE, et al. Man- agement of spontaneous pneumothorax: an American College of Chest Physicians Delphi consensus statement. Chest 2001; 119:590-602. [CrossRef]

Hiraki T, Gobara H, Iguchi T, Fujiwara H, Matsui Y, Kanazawa S. Radiofrequency ablation for early-stage nonsmall cell lung cancer. Biomed Res Int 2014; 2014:152087. [CrossRef]

Zhu JC, Yan TD, Morris DL. A systematic review of radiofrequency ablation for lung tumors. Ann Surg Oncol 2008; 15:1765-1774. [CrossRef]

Lencioni R, Crocetti L, Cioni R, et al. Response to radiofrequency ablation of pulmonary tu- mours: a prospective, intention-to-treat, multi- centre clinical trial (the RAPTURE study). Lancet Oncol 2008; 9:621-628. [CrossRef]

Chua TC, Sarkar A, Saxena A, Glenn D, Zhao J, Morris DL. Long-term outcome of image-guid- ed percutaneous radiofrequency ablation of lung metastases: an open-labeled prospective trial of 148 patients. Ann Oncol 2010; 21:2017- 2022. [CrossRef]

Matsui Y, Hiraki T, Gobara H, et al. Long-term sur- vival following percutaneous radiofrequency ab- lation of colorectal lung metastases. J Vasc Interv Radiol 2015; 26:303-310. [CrossRef]

Gillams A, Khan Z, Osborn P, Lees W. Survival after radiofrequency ablation in 122 patients with inoperable colorectal lung metastases. Cardiovasc Intervent Radiol 2013; 36:724-730. [CrossRef]

Petre EN, Jia X, Thornton RH, et al. Treatment of pulmonary colorectal metastases by radiofre- quency ablation. Clin Colorectal Cancer 2013; 12:37-44. [CrossRef]

Hiraki T, Gobara H, Iguchi T, Fujiwara H, Mat- sui Y, Kanazawa S. Radiofrequency ablation as treatment for pulmonary metastasis of colorectal cancer. World J Gastroenterol 2014; 20:988-996. [CrossRef]

Yan TD, King J, Sjarif A, et al. Percutaneous ra- diofrequency ablation of pulmonary metasta- ses from colorectal carcinoma: prognostic de- terminants for survival. Ann Surg Oncol 2006; 13:1529-1537. [CrossRef]

Simon CJ, Dupuy DE, DiPetrillo TA, et al. Pulmo- nary radiofrequency ablation: long term safety and efficacy in 153 patients. Radiology 2007; 243:268-275. [CrossRef]

Yamakado K, Hase S, Matsuoka T, et al. Radiofre- quency ablation for the treatment of unresect- able lung metastases in patients with colorectal cancer: a multicentre study in Japan. J Vasc In- terv Radiol 2007; 18:393-398. [CrossRef]

Thanos L, Mylona S, Ptohis N, et al. Percutaneous radiofrequency thermal ablation in the man- agement of lung tumors: presentation of clini- cal experience on a series of 35 patients. Diagn Interv Radiol 2009; 15:290-296.

Thanos L, Mylona S, Pomoni M, et al. Percuta- neous radiofrequency thermal ablation of pri- mary and metastatic lung tumors. Eur J Cardio- thorac Surg 2006; 30:797-800. [CrossRef]

Suh RD, Wallace AB, Sheehan RE, Heinze SB, Goldin JG. Unresectable pulmonary malignan- cies: CT-guided percutaneous radiofrequency ablation--preliminary results. Radiology 2003; 229:821-829. [CrossRef]

Yamagami T, Kato T, Hirota T, Yoshimatsu R, Matsumoto T, Nishimura T. Pneumothorax as a complication of percutaneous radiofrequency ablation for lung neoplasms. J Vasc Interv Radi- ol 2006; 17:1625-1629. [CrossRef]

Nour-Eldin NE, Naguib NN, Saeed AS, et al. Risk factors involved in the development of pneu- mothorax during radiofrequency ablation of lung neoplasms. AJR Am J Roentgenol 2009; 193:W43-48. [CrossRef]

Garetto I, Busso M, Sardo D, et al. Radiofre- quency ablation of thoracic tumours: lessons learned with ablation of 100 lesions. Radiol Med 2014; 119:33-40. [CrossRef]

Crabtree T, Puri V, Timmerman R, et al. Treat- ment of stage I lung cancer in high-risk and inoperable patients: comparison of prospec- tive clinical trials using stereotactic body ra- diotherapy (RTOG 0236), sublobar resection (ACOSOG Z4032), and radiofrequency ablation (ACOSOG Z4033). J Thorac Cardiovasc Surg 2013; 145:692-699. [CrossRef]

Zimmermann FB, Geinitz H, Schill S, et al. Ste- reotactic hypofractionated radiation therapy for stage I non-small cell lung cancer. Lung Cancer 2005; 48:107-114. [CrossRef]

Fakiris AJ, McGarry RC, Yiannoutsos CT, et al. Stereotactic body radiation therapy for ear- ly-stage non-small-cell lung carcinoma: four- year results of a prospective phase II study. Int J Radiat Oncol Biol Phys 2009; 75:677-682. [CrossRef]

Lagerwaard FJ, Verstegen NE, Haasbeek CJ, et al. Outcomes of stereotactic ablative radiother- apy in patients with potentially operable stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2012; 83:348-353. [CrossRef]

Casiraghi M, De Pas T, Maisonneuve P, et al. A 10-year single-center experience on 708 lung metastasectomies: the evidence of the "inter- national registry of lung metastases." J Thorac Oncol 2011; 6:1373-1378. [CrossRef]

Widder J, Klinkenberg TJ, Ubbels JF, Wiegman EM, Groen HJ, Langendijk JA. Pulmonary oligometas- tases: metastasectomy or stereotactic ablative ra- diotherapy? Radiother Oncol 2013; 107:409-413. [CrossRef]

___

Diagnostic and Interventional Radiology
  • ISSN: 1305-3612
  • Yayın Aralığı: Yılda 6 Sayı
  • Başlangıç: 2001
  • Yayıncı: AVES Yayıncılık

9.8b5.9b

Sayıdaki Diğer Makaleler

The role of multidetector CT in local staging and evaluation of retroperitoneal surgical margin involvement in colon cancer

Funda Dinç ELİBOL, Funda OBUZ, Selman SÖKMEN, Cem TERZİ, Aras Emre CANDA, Özgül SAĞOL, SÜLEN SARIOĞLU

AngioVac extraction of intra-atrial hepatoma masquerading as PICC-associated thrombus

Samir ABBOUD, Kirtee RAPARIA, M. Julianne UBAGO, Scott RESNİCK

The endovenous ASVAL method: principles and preliminary results

Mehmet Mahir ATASOY, Levent OĞUZKURT

A novel modified PAIR technique using a trocar catheter for percutaneous treatment of liver hydatid cysts: a six-year experience

Alaaddin NAYMAN, İbrahim GÜLER, Suat KESKİN, Tuba Berra ERDEM, Hale BORAZAN, Ahmet KÜÇÜKAPAN, Hüseyin ÖZBİNER, Abdussamed BATUR, ERSEN ERTEKİN, Bahadır FEYZİOĞLU, Osman KOÇ, Hasan Emin KAYA, Osman TEMİZÖZ, Adil KARTAL, Orhan ÖZBEK

Clinical outcome of angiosome-oriented infrapopliteal percutaneous transluminal angioplasty for isolated infrapopliteal lesions in patients with critical limb ischemia

Eui Yong JEON, Young Kwon CHO, Dae Young YOON, Dae Jung KİM, Jeong Joo WOO

Radiofrequency ablation for lung tumors: outcomes, effects on survival, and prognostic factors

Okan AKHAN, Ezgi GÜLER, DEVRİM AKINCI, Türkmen ÇİFTÇİ, Ilgaz Çağatay KÖSE

Increased x-ray attenuation in malignant vs. benign mediastinal nodes in an orthotopic model of lung cancer

Paul FLECHSİG, Peter CHOYKE, Clemens KRATOCHWİL, Arne WARTH, Gerald ANTOCH, Tim Holland LETZ, RATH DANIEL, Viktoria EICHWALD, E. Peter HUBER, Hans-Ulrich KAUCZO, Uwe HABERKORN, L. Frederik GİESEL

Imaging features of Burkitt lymphoma in pediatric patients

Betül Emine DERİNKUYU, Öznur BOYUNAĞA, Çiğdem ÖZTUNALI, Funda TEKKEŞİN, ÇAĞRI DAMAR, Ayşe GÜL ALIMLI, Arzu OKUR

In vivo and ex vivo measurements: noninvasive assessment of alcoholic fatty liver using 1H-MR spectroscopy

Daniel KEESE, Hüdayi KORKUSUZ, Frank HUEBNER, Dmitry NAMGALADZE, Bahram RASCHİDİ, J. Thomas VOGL

Editor's Recognition Awards and acknowledgements

Nevzat KARABULUT